SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

09 Feb 2022 Evaluate
Net sales declined -29.77%  to  Rs. 26230.50 million from Rs. 37351.70 millions.The Company to register a -67.41%  fall in the net profit for the quarter ended December 2021.The company reported a degrowth in operating Profit to 3472.00 millions from 11341.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 26230.50 37351.70 -29.77 83999.80 117096.60 -28.26 158236.80 133707.70 18.35
Other Income 1312.90 1583.20 -17.07 2576.10 3224.50 -20.11 5898.60 2434.30 142.31
PBIDT 3472.00 11341.20 -69.39 12240.60 34662.70 -64.69 47096.80 29412.90 60.12
Interest 35.40 58.60 -39.59 120.40 227.50 -47.08 286.80 979.10 -70.71
PBDT 3436.60 11282.60 -69.54 12120.20 34435.20 -64.80 46810.00 28433.80 64.63
Depreciation 1012.00 1222.10 -17.19 3140.30 3639.20 -13.71 4879.90 4733.30 3.10
PBT 2424.60 10060.50 -75.90 8979.90 30796.00 -70.84 41930.10 23700.50 76.92
TAX 26.50 2701.40 -99.02 2454.30 8392.30 -70.76 10801.00 4931.70 119.01
Deferred Tax -861.60 17.50 -5023.43 -1088.60 48.70 -2335.32 367.60 8.80 4077.27
PAT 2398.10 7359.10 -67.41 6525.60 22403.70 -70.87 31129.10 18768.80 65.86
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 13.24 30.36 -56.41 14.57 29.60 -50.77 29.76 22.00 35.30

Aurobindo Pharma Share Price

1620.10 60.05 (3.85%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: